DD294864A5 - Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie - Google Patents

Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie Download PDF

Info

Publication number: DD294864A5
Authority: DD; German Democratic Republic
Prior art keywords: naftopidil; dysuria; improved; treatment; prostate hypertrophy
Prior art date: 1989-06-07

Application number

DD90341372A

Other languages

German (de)

English (en)

Inventor

Gisbert Sponer

Ulrich Reicke

Michael Nelboeck-Hochstetter

Original Assignee

��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-07

Filing date

1990-06-06

Publication date

1991-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6382247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD294864(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-06-06 Application filed by ��@��@��k�� filed Critical ��@��@��k��

1991-10-17 Publication of DD294864A5 publication Critical patent/DD294864A5/de

Links

HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 title claims abstract description 11
206010020880 Hypertrophy Diseases 0.000 title claims abstract 5
206010013990 dysuria Diseases 0.000 title claims abstract 5
210000002307 prostate Anatomy 0.000 title claims abstract 5
229950005705 naftopidil Drugs 0.000 title claims description 9
238000002560 therapeutic procedure Methods 0.000 title claims 2
150000003839 salts Chemical class 0.000 claims abstract 2
230000027939 micturition Effects 0.000 claims 3
210000002700 urine Anatomy 0.000 claims 3
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 2
150000001875 compounds Chemical class 0.000 claims 2
238000011156 evaluation Methods 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
229920002307 Dextran Polymers 0.000 claims 1
208000001953 Hypotension Diseases 0.000 claims 1
206010027566 Micturition urgency Diseases 0.000 claims 1
241000700159 Rattus Species 0.000 claims 1
230000003187 abdominal effect Effects 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
239000002671 adjuvant Substances 0.000 claims 1
208000003455 anaphylaxis Diseases 0.000 claims 1
230000003276 anti-hypertensive effect Effects 0.000 claims 1
229940076810 beta sitosterol Drugs 0.000 claims 1
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims 1
NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
239000008298 dragée Substances 0.000 claims 1
239000003814 drug Substances 0.000 claims 1
239000000975 dye Substances 0.000 claims 1
230000000694 effects Effects 0.000 claims 1
239000000796 flavoring agent Substances 0.000 claims 1
-1 flavorings Substances 0.000 claims 1
235000019634 flavors Nutrition 0.000 claims 1
238000009472 formulation Methods 0.000 claims 1
208000021822 hypotensive Diseases 0.000 claims 1
230000001077 hypotensive effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
239000003921 oil Substances 0.000 claims 1
235000019198 oils Nutrition 0.000 claims 1
239000004006 olive oil Substances 0.000 claims 1
235000008390 olive oil Nutrition 0.000 claims 1
229940124531 pharmaceutical excipient Drugs 0.000 claims 1
239000000902 placebo Substances 0.000 claims 1
229940068196 placebo Drugs 0.000 claims 1
239000000419 plant extract Substances 0.000 claims 1
201000004240 prostatic hypertrophy Diseases 0.000 claims 1
KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 1
229950005143 sitosterol Drugs 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
208000024891 symptom Diseases 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910004298 SiO 2 Inorganic materials 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)

DD90341372A 1989-06-07 1990-06-06 Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie DD294864A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3918543A DE3918543A1 (de)	1989-06-07	1989-06-07	Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie

Publications (1)

Publication Number	Publication Date
DD294864A5 true DD294864A5 (de)	1991-10-17

Family

ID=6382247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90341372A DD294864A5 (de)	1989-06-07	1990-06-06	Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie

Country Status (19)

Country	Link
US (1)	US5026706A (fr)
EP (1)	EP0401653B1 (fr)
JP (1)	JPH062673B2 (fr)
KR (1)	KR0131452B1 (fr)
AT (1)	ATE84416T1 (fr)
AU (1)	AU625766B2 (fr)
CA (1)	CA2017619C (fr)
DD (1)	DD294864A5 (fr)
DE (2)	DE3918543A1 (fr)
DK (1)	DK0401653T3 (fr)
ES (1)	ES2054147T3 (fr)
GR (1)	GR3007328T3 (fr)
HK (1)	HK46996A (fr)
HU (1)	HU206976B (fr)
IE (1)	IE62937B1 (fr)
IL (1)	IL94601A (fr)
PH (1)	PH26690A (fr)
PT (1)	PT94268B (fr)
ZA (1)	ZA904338B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5474994A (en) *	1992-05-26	1995-12-12	Recordati S.A., Chemical And Pharmaceutical Company	Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) *	1992-02-25	1995-09-25	Recordati Chem Pharm	Derivati benzopiranici e benzotiopiranici
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer
TW536402B (en)	1998-06-26	2003-06-11	Yamanouchi Pharma Co Ltd	Pharmaceutical composition for the therapy of voiding dysfunction
AU7736300A (en)	1999-09-30	2001-04-30	Hollis-Eden Pharmaceuticals, Inc.	Therapeutic treatment of androgen receptor driven conditions
JP2001288115A (ja) *	2001-02-07	2001-10-16	Yamanouchi Pharmaceut Co Ltd	下部尿路症治療剤
BR102012000187A2 (pt) *	2012-01-05	2018-04-10	Univ Rio De Janeiro	Derivados n-fenilpiperazínicos antagonistas de adrenoceptores a1a, a1d e de receptores 5-ht1a no tratamento da hiperplasia prostática benigna, composições farmacêuticas contendo os mesmos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL175059C (nl) *	1974-02-23		Boehringer Mannheim Gmbh	Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten.

1989
- 1989-06-07 DE DE3918543A patent/DE3918543A1/de active Granted
1990
- 1990-05-04 PH PH40616A patent/PH26690A/en unknown
- 1990-05-28 CA CA002017619A patent/CA2017619C/fr not_active Expired - Lifetime
- 1990-05-30 EP EP90110207A patent/EP0401653B1/fr not_active Expired - Lifetime
- 1990-05-30 ES ES90110207T patent/ES2054147T3/es not_active Expired - Lifetime
- 1990-05-30 DE DE9090110207T patent/DE59000748D1/de not_active Expired - Fee Related
- 1990-05-30 AT AT90110207T patent/ATE84416T1/de not_active IP Right Cessation
- 1990-05-30 US US07/530,362 patent/US5026706A/en not_active Expired - Lifetime
- 1990-05-30 DK DK90110207.9T patent/DK0401653T3/da active
- 1990-06-01 JP JP2144272A patent/JPH062673B2/ja not_active Expired - Lifetime
- 1990-06-03 IL IL9460190A patent/IL94601A/en unknown
- 1990-06-05 AU AU56282/90A patent/AU625766B2/en not_active Ceased
- 1990-06-05 PT PT94268A patent/PT94268B/pt not_active IP Right Cessation
- 1990-06-06 IE IE201490A patent/IE62937B1/en not_active IP Right Cessation
- 1990-06-06 ZA ZA904338A patent/ZA904338B/xx unknown
- 1990-06-06 DD DD90341372A patent/DD294864A5/de not_active IP Right Cessation
- 1990-06-06 HU HU903515A patent/HU206976B/hu not_active IP Right Cessation
- 1990-06-07 KR KR1019900008320A patent/KR0131452B1/ko not_active Expired - Fee Related
1993
- 1993-03-12 GR GR920403077T patent/GR3007328T3/el unknown
1996
- 1996-03-14 HK HK46996A patent/HK46996A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL94601A0 (en)	1991-04-15
HUT54494A (en)	1991-03-28
HU903515D0 (en)	1990-10-28
EP0401653A2 (fr)	1990-12-12
IL94601A (en)	1994-06-24
AU625766B2 (en)	1992-07-16
DE59000748D1 (de)	1993-02-25
HK46996A (en)	1996-03-22
ATE84416T1 (de)	1993-01-15
CA2017619A1 (fr)	1990-12-07
EP0401653B1 (fr)	1993-01-13
DK0401653T3 (da)	1993-03-29
PT94268B (pt)	1997-01-31
JPH062673B2 (ja)	1994-01-12
PT94268A (pt)	1991-02-08
PH26690A (en)	1992-09-15
IE902014L (en)	1990-12-07
GR3007328T3 (fr)	1993-07-30
JPH0324014A (ja)	1991-02-01
EP0401653A3 (fr)	1991-07-17
US5026706A (en)	1991-06-25
KR910000152A (ko)	1991-01-29
IE62937B1 (en)	1995-03-08
ZA904338B (en)	1991-03-27
DE3918543C2 (fr)	1991-06-06
HU206976B (en)	1993-03-01
KR0131452B1 (ko)	1998-04-17
CA2017619C (fr)	1995-06-20
ES2054147T3 (es)	1994-08-01
AU5628290A (en)	1990-12-13
DE3918543A1 (de)	1990-12-13

Legal Events

Date	Code	Title	Description
1996-08-14	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69828881T2 (de)	2006-01-19	Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen
DE69420776T2 (de)	2000-05-18	Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
EP1513533B1 (fr)	2010-03-17	Combinaison d'agents actifs pharmaceutiques et utilisation
DE3918543C2 (fr)	1991-06-06
DE2824165A1 (de)	1978-12-21	Arzneimittel mit angstneurosen und angstaehnliche neurosen beseitigender wirkung und verfahren zum zubereiten des arzneimittels
EP0618797B1 (fr)	2000-03-15	Preparations pharmaceutiques renfermant du bilobalide pour le traitement des etats de tension nerveuse et d'anxiete
EP0331014A2 (fr)	1989-09-06	L'utilisation des inhibiteurs de l'enzyme de conversion pour la prophylaxie du diabète
EP1001756B1 (fr)	2004-04-07	Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
DD242749A5 (de)	1987-02-11	Verbesserte entzuendungshemmende zusammensetzungen und verfahren
DE3785555T2 (de)	1993-08-19	Verwendung von guaifenesin zur behandlung urologischer beschwerden.
Lask	1953	Treatment of Vomiting of Pregnancy with Antihistamines
US5128141A (en)	1992-07-07	Association of physiologically dosed vitamin a and of various active principles having a therapeutical activity
DE60019591T2 (de)	2006-03-02	Behandlung oder hemmung von koronarimplantat vasospasm
DE69936773T2 (de)	2008-04-30	Behandlung von depression und zusammensetzungen dazu
DE1617336C2 (de)	1982-07-01	Arzneimittel gegen Angina pectoris
EP3090638A1 (fr)	2016-11-09	Complément alimentaire destiné au traitement de carences en vitamine d3
DE2352618A1 (de)	1974-08-29	Arzneimittel zur behandlung des parkinsonismus
DE3511236C2 (fr)	1991-05-02
EP1474134B1 (fr)	2011-08-17	Preparation combinee de l'inhibiteur d'echange sodium-hydrogene cariporide et de ramipril pour prevenir ou inhiber l'insuffisance cardiaque
DE19531463A1 (de)	1997-02-27	Pharmazeutische Zubereitung
EP0523591A2 (fr)	1993-01-20	Utilisation d'un extrait de Kava et de ses composants
DE2505913A1 (de)	1975-08-28	Arzneimittel zur oralen behandlung von nicht-tumorartigen gastroduodenalbeschwerden und verfahren zu seiner herstellung
Kloke	1993	Die neu standardisierte Morphinlösung NRF 2.4 zur Dosisfindung bei Ersteinstellung mit Morphin und als Zusatzmedikation bei einer Basistherapie mit retardierten Morphinsulfattabletten
DE4112824A1 (de)	1992-10-22	Verwendung von nelkenoel zur behandlung von bph
DE4206375A1 (de)	1993-09-02	Arzneimittel zur behandlung von morbus alzheimer